September 2008 – Oral Cancer News

Eating walnuts slows cancer growth, laboratory study finds

Source: news.biocompare.com Author: staff Snack-sized quantities of walnuts slow cancer growth in mice, reports a Marshall University pilot study published in the current issue of the peer-reviewed journal Nutrition and Cancer. Researcher W. Elaine Hardman, Ph.D., of Marshall's Joan C. Edwards School of Medicine said the study was designed to determine whether mice that got part of their calories by eating walnuts had slower breast cancer growth than a group eating a diet more typical of the American diet. "When we fed the mice the walnuts, the growth rate of the tumors they had was dramatically suppressed," Hardman said. The mice ate a diet in which 18.5 percent of the daily calories -- the equivalent of two servings for humans -- came from walnuts. Tumors in the walnut-fed group took twice as long to double in size as tumors in the control group, the article reports. The study is believed to be the first to look at the impact of walnut consumption on cancer growth. "It's always very good to find something that will slow the growth of tumors without being toxic chemotherapy," said Hardman, who has spent 15 years studying the role of diet in cancer. Walnuts have at least three components that could account for their cancer-slowing effect, Hardman said. They are high in omega-3 fatty acids, which have been shown to slow cancer growth. They also include antioxidants and components called phytosterols, both of which have shown cancer-slowing effects in other studies. While the pilot study was [...]

Oral Cancer Foundation News Team - A2008-09-30T06:59:48-07:00September, 2008|Oral Cancer News|

New findings show cancer prevention effects of black raspberries, blueberries, olive leaves and green tea

Source: www.naturalnews.com Author: David Gutierrez Three studies presented at the American Association for Cancer Research's Sixth Annual International Conference on Frontiers in Cancer Prevention Research in Philadelphia have demonstrated the powerful cancer-fighting benefits of dark berries, green tea and olive leaves, and suggest that gels and beverages may some day be used to prevent against cancer and tumor growth. In the first study, researchers from Ohio State University discovered that a gel based on freeze-dried black raspberries helps prevent precancerous mouth tumors (lesions) from becoming malignant. "This gel appears to be a valid means of delivering anthocyanins and other cancer-preventing compounds directly to precancerous cells, since it slowed or reduced lesion progression in about two-thirds of study participants," said researcher Susan Mallery. According to the American Cancer Society, oral squamous cell carcinoma is one of the deadliest forms of cancer, causing 7,500 deaths each year in the United States. Because no chemopreventive agent or treatment method other than radical mouth surgery exists, even those who survive the cancer often emerge significantly disfigured. And even in many cases where tumors are fully removed, they still recur. "Oral cancer is a debilitating disease and there is a desperate need for early detection and management of precancerous lesions," said Mallery. Most mouth cancer begins as small, noncancerous lesions in the mouth that are difficult to detect. It was these lesions that were treated in the Ohio State University study. Researchers carried out the study on 20 participants who had identifiable precancerous mouth lesions [...]

Oral Cancer Foundation News Team - A2008-09-29T18:53:12-07:00September, 2008|Oral Cancer News|

Knicks Prez Donnie Walsh had oral cancer surgery soon after draft

Source: www.pacersdigest.com Author: Peter Vecsey Donnie Walsh asked me not to make a big deal of this when I requested permission to break the news . . . so I won't . . . though, I'm sure we all agree, it is a big deal. Four days after last June's draft, the Knicks' president, 67, entered Memorial Sloan-Kettering Cancer Center and went under the knife for one hour. An uncontrollable 50-year urge to smoke vanished along with the cancerous part of his tongue. "My doctor says he got it all," Walsh said. "Luckily, it was caught quickly before it could spread. Numerous pre- and post-op scans of his head and neck concurred it had been contained. Physically, Walsh is almost back to normal. His mouth remains a little numb and his speech only betrays him when a conversation becomes lengthy. "It's like I have marbles in my mouth. But you can't really tell there's something missing unless I stick out my tongue." "Spare me," I promptly replied, "I'll take your word for it. "Something tells me your French kissing days may be over." Consensual gallows humor between New Yorkers who've been friends for almost half their adult lives is not only expected but required. Anything to lighten his psychological load is licensed; Donnie's stare down with mortality admittedly shook him up like the grade-school nuns who habitually harped on the Hereafter. Two of Donnie's closest college buddies died in the past three years. Additionally, an inordinately large percentage of his [...]

Oral Cancer Foundation News Team - A2008-09-29T18:52:48-07:00September, 2008|Oral Cancer News|

Sanofi Pasteur MSD’s HPV vaccine Gardasil(R) wins Prix Galien award

Source: www.medicalnewstoday.com Author: staff The two HPV vaccines currently licensed for use in the UK were jointly awarded the coveted Prix Galien Medal for Innovation at a ceremony held on Wednesday evening in the Palace of Westminster, House of Commons. "We are absolutely delighted at the recognition given to the world's leading HPV vaccine Gardasil® - this award reflects the work of many people, all around the world, involved in making the dream of a cancer vaccine a reality", said Dr Nicholas Kitchin, Medical Director, accepting the award on behalf of the Sanofi Pasteur MSD team. "Both companies have developed the technology of HPV vaccines down different paths," he continued, "we chose a quadrivalent vaccine strategy, targeting a broader range of HPV-related genital disease than cervical cancer alone, with the aim of delivering additional benefits for patients and healthcare systems." The joint award for the two HPV vaccines, developed by Sanofi Pasteur MSD and GSK, was presented by Andrew Lansley CBE MP, Shadow Secretary of State for Health. The distinguished panel of seven judges, chaired by Professor Sir Michael Rawlins, selected the HPV vaccines as the winners from seven innovative products that reached the final. Vaccines have won in four of the last five Prix Galien awards and the UK award for Gardasil® follows similar success in Prix Galien competitions in the USA and France. Current experience with the four-type HPV vaccine Thirty years after the discovery that human papillomavirus (HPV) can cause cervical cancer, 15 years after the start [...]

Oral Cancer Foundation News Team - A2008-09-29T18:53:38-07:00September, 2008|Oral Cancer News|

HPV increases men’s risk for oral cancer, prompts calls for vaccine: pathology expert Dr. Shashi Pawar on HPV health concerns for men

Source: www.prweb.com Author: press release HPV, the human papillomavirus, is well known for its role in causing cervical cancer in women - so much so, in fact, that the National Institutes of Health recommend all girls be vaccinated against the virus when they are 11 or 12, prior to becoming sexually active. However, recent research shows that women are not the only ones at risk for developing HPV-related cancers. Oral cancers caused by the virus are increasing rapidly in men, and researchers suggest HPV may soon overtake tobacco use as the leading cause of these cancers of the mouth, tongue, throat and tonsils. "The human papillomavirus is one of the most insidious and dangerous sexually transmitted diseases for women, as it has been linked to a vast majority of cervical cancers," explains Dr. Shashi Pawar, PhD, FACMG, Director of Genetics at Acupath Laboratories. "We are now seeing the effects of HPV infection in men, and the marked increase in oral cancer - coupled with the well-known increased risk for penile and anal cancers - suggests that both sexes face equally serious health consequences from this virus," Dr. Pawar notes. Cumulative research spurs call for men's vaccine A benchmark study that tracked more than 30 years of oral cancer data from the National Cancer Institute found that the rate of oral cancer caused by the HPV virus, rather than lifestyle habits such as smoking or chewing tobacco, has risen steadily since 1973 and is now about even with the incidence rate [...]

Oral Cancer Foundation News Team - A2009-05-08T19:03:42-07:00September, 2008|Oral Cancer News|

Smoking impact images to appear on cigarette packs

Source: www.politics.co.uk Author: staff The government wants to shock smokers into quitting by putting graphic pictures of the damage caused by smoking on cigarette packs. From Wednesday picture warnings will begin replacing the written warnings currently on packets in a bid to improve on the 1.9 million fewer smokers seen since 1982. The new images show rotting teeth and lungs, throat cancer and a 'flaccid cigarette' – the "grim reality" of the effects smoking can have on health, as chief medical officer Sir Liam Donaldson says. "These new stark picture warnings emphasise the harsh health realities of continuing to smoke. I hope they will make many more think hard about giving up, and get the help they need to stop smoking for good." Britain is not the first country to use graphic warnings: Canada introduced them in 2001 and saw 31 per cent of ex-smokers claiming the pictures had motivated them to quit. Anti-smoking campaigners have welcomed the images, which come into force from October 1st. Action on Smoking and Health's (Ash) director Deborah Arnott backed existing evidence suggesting the images make smokers quit. And she called on the government to legislate to require the removal of pack branding to maximise their impact, as research shows this has the greatest impact. Cancer Research UK's head of tobacco control, Elspeth Lee, said her organisation would back an amendment to current EU legislation allowing picture warnings to be placed on the front as well as the back of packs, as in Australia [...]

Oral Cancer Foundation News Team - A2008-09-28T21:26:53-07:00September, 2008|Oral Cancer News|

Selective neck dissection effective for head and neck squamous cell carcinoma with regional metastases

Source: www.docguide.com Author: Mary Beth Nierengarten Selective neck dissection, rather than comprehensive neck dissection, is an effective treatment for many patients with regional nodal metastases from head and neck squamous cell carcinoma, investigators reported here at the American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) 2008 Annual Meeting & OTO EXPO. Lead author Peter Shepard, MD, Department of Surgery, University of Wisconsin School of Medicine, Madison, Wisconsin, presented the study findings in a poster session on September 21. In their study, Dr. Shepard and colleagues retrospectively evaluated 156 patients with clinically-positive regional nodal metastases from head and neck squamous cell carcinoma in whom neck dissection was part of the initial treatment. Of the 156 patients, 69 underwent selective neck dissection (SND) and 87 underwent radical or modified radical neck dissection (R/MRND). Most patients (81%) also received postoperative radiotherapy. Overall, regional recurrences occurred in 8.6% of patients who underwent SND and 22% of patients who underwent R/MRND. When adjusting for differences in nodal and primary tumour stage, year of surgery, primary tumour site, extracapsular spread, and postoperative radiotherapy, multivariate analysis showed a significantly lower regional recurrence rate in the SND group (P = .02). No statistically significant differences were seen in overall survival; 5-year overall survival for SND and R/MRND of 47% and 33%, respectively (P = .14). Similarly, no significant differences were found in local control or distant local control, with 3-year local control rates of 87% and 83% (P = .89) and distant control rates of [...]

Oral Cancer Foundation News Team - A2008-09-28T21:26:35-07:00September, 2008|Oral Cancer News|

Improvements for patients with oral mucositis

Source: cancerfocus.net Author: staff New data show that Caphosol® (www.caphosol.com), an advanced electrolyte solution, significantly limits the occurrence and severity of oral mucositis (OM) in cancer patients undergoing chemotherapy and radiation therapy. The data, which contain the final results from a prospective observational study sponsored by EUSA Pharma, were presented today at the 50th annual meeting of the American Society of Therapeutic Radiology and Oncology (ASTRO), and demonstrate that Caphosol use is associated with high levels of medication compliance and patient and physician satisfaction. The latest findings expand upon the growing body of evidence of the benefits of Caphosol in the management of OM and related symptoms in patients with various types of cancer. "Oral mucositis is a common, debilitating side effect of chemotherapy and radiation therapy, resulting from erosion of epithelial cells in the oral cavity (cells lining the surface of the throat and esophagus) during therapy," said principal investigator Marilyn L. Haas, PhD, RN, CNS, ANP-C, Nurse Practitioner, Carolina Clinical Consultant. "Patients with oral mucositis often experience severe pain, difficulty eating and swallowing, and greater susceptibility to infection. The registry data suggests that CAPHOSOL, a supersaturated electrolyte oral rinse, has a significant positive impact on the occurrence and severity of oral mucositis, and is highly regarded by patients and physicians." Dr. Haas and colleagues reported data from 68 patients with head and neck (HN) cancer enrolled in an open-label, observational registry maintained at 26 treatment centers in the U.S. The patients were considered at high risk of developing [...]

Oral Cancer Foundation News Team - A2008-09-28T21:23:42-07:00September, 2008|Oral Cancer News|

HPV increases men’s risk for oral cancer, prompts calls for vaccine: pathology expert Dr. Shashi Pawar on HPV health concerns for men

Source: www.prweb.com Author: press release HPV, the human papillomavirus, is well known for its role in causing cervical cancer in women - so much so, in fact, that the National Institutes of Health recommend all girls be vaccinated against the virus when they are 11 or 12, prior to becoming sexually active. However, recent research shows that women are not the only ones at risk for developing HPV-related cancers. Oral cancers caused by the virus are increasing rapidly in men, and researchers suggest HPV may soon overtake tobacco use as the leading cause of these cancers of the mouth, tongue, throat and tonsils. "The human papillomavirus is one of the most insidious and dangerous sexually transmitted diseases for women, as it has been linked to a vast majority of cervical cancers," explains Dr. Shashi Pawar, PhD, FACMG, Director of Genetics at Acupath Laboratories. "We are now seeing the effects of HPV infection in men, and the marked increase in oral cancer - coupled with the well-known increased risk for penile and anal cancers - suggests that both sexes face equally serious health consequences from this virus," Dr. Pawar notes. Cumulative research spurs call for men's vaccine A benchmark study that tracked more than 30 years of oral cancer data from the National Cancer Institute found that the rate of oral cancer caused by the HPV virus, rather than lifestyle habits such as smoking or chewing tobacco, has risen steadily since 1973 and is now about even with the incidence rate [...]

Oral Cancer Foundation News Team - A2008-09-28T21:27:18-07:00September, 2008|Oral Cancer News|

Free nicotine content and strategic marketing of moist snuff tobacco products in the United States: 2000–2006

Source: Harvard School of Public Health, Boston, Massachusetts, USA Authors: H R Alpert, H Koh, G N Connolly Background: From 2000 to 2006, moist snuff sales have increased and now account for 71% of the smokeless tobacco market. Previous research has shown that major manufacturers of smokeless tobacco products manipulated free nicotine, the form most readily absorbed, to promote tolerance and addiction. Aim: This study examines the possibility that company-specific and brand-specific strategies of the major moist snuff manufacturers involve controlling free nicotine content and ease of dosing with products that are designed and targeted to specific groups. This study looks at the current total US moist snuff market with product design data from the Massachusetts Department of Public Health; moist snuff use from the National Survey on Drug Use and Health; market data from ACNielsen; and magazine advertising expenditures from TNS Media Intelligence. Results: (1) The levels of free nicotine of moist snuff products have increased over time for several major manufacturers; (2) the number and variety of sub-brands have increased over time; (3) changes in design, as reflected by variation in free nicotine associated with pH or tobacco leaf, or both, have enhanced the ease and uniformity of dosing; (4) marketing through price and advertising has increased; and (5) youth use has increased. Conclusion: A combination of factors including brand proliferation, control of free nicotine and product design has most likely resulted in the expanded consumption of moist snuff, particularly among young people.

Oral Cancer Foundation News Team - A2008-09-28T21:27:41-07:00September, 2008|Oral Cancer News|